CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

0  0%
Previous Close 1.14
Open 1.13
Price To Book 4.07
Market Cap 25650000
Shares 22,500,000
Volume 90,130
Short Ratio 1.94
Av. Daily Volume 170,598

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 failed to meet endpoint - July 2016
Piclidenoson (CF101)
Phase 2 data due 1Q 2019.
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 3 commencement of enrollment announced October 30, 2017.
Piclidenoson (CF101)
Rheumatoid arthritis
Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 trial initiation announced August 21, 2018.
Piclidenoson (CF101)
Phase 2 data due 1H 2019.
Namodenoson (CF102)
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Watch These 4 Healthcare Stocks Set The Pace On Monday (2/4/19)
  2. Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug
  3. 4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)
  4. Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal
  5. Can-Fite BioPharma CEO Letter to Shareholders
  6. Can-Fite BioPharma Announces Registered Direct Offering
  7. Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent
  8. Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference
  9. Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC
  10. Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update
  11. Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert
  12. Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19
  13. Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference
  14. Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018
  15. Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD)
  16. Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year
  17. Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update
  18. Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
  19. Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis
  20. Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China